+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group



A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group



British Journal of Cancer 68(4): 813-818



Proliferation of drug resistant tumour following chemotherapy is the principal cause of treatment failure in small cell lung cancer (SCLC). Verapamil has been shown to partially restore drug sensitivity in tumour cells rendered resistant in vitro. The results of the first large-scale randomised study of a resistance modifying drug given in conjunction with chemotherapy in cancer patients are reported. Two hundred and twenty-six patients have been entered. All patients received four cycles of cyclophosphamide (750 mg m-2), doxorubicin (40 mg m-2) and vincristine (1.4 mg m-2) on Day 1 and etoposide (75 mg m-2) on Days 1, 2 and 3, repeated at 21 day intervals. Those patients randomised to the verapamil arm received oral verapamil 120 mg qid for 5 days with each course of chemotherapy. Similar numbers of cycles of protocol treatment were given in both arms with over 75% of patients completing all four cycles. There were no significant differences in general toxicities between the two arms, except for more severe alopecia in the verapamil treatment group (P = 0.045). There was no significant difference in cardiovascular or haematological toxicity, although the median nadir white cell count after Cycle 1 chemotherapy was lower in the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil arm (P = 0.031). No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data were seen. The absence of a significant improvement in response or survival using verapamil may relate to the low blood levels of verapamil seen in the clinic (0.8 microM), in contrast to those known to be maximally active in vitro (> 6 microM) or to the presence of other cellular mechanisms by which drug resistance develops.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045101397

Download citation: RISBibTeXText

PMID: 8398713


Related references

Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. Japanese Journal of Clinical Oncology 24(5): 275-281, 1994

Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. Oncology 11(9 Suppl 10): 98-102, 1998

First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience. Seminars in Oncology 26(5 Suppl 15): 44-51, 1999

Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research. Lung Cancer 12 Suppl 1: S125-S132, 1995

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010): 899-909, 1995

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IiibIv non-small cell lung cancer: a phase Ii study of the West Japan Thoracic Oncology Group (Wjtog) 9908. Lung Cancer 43(1): 93-100, 2004

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43(1): 93-100, 2003

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 7(11): 1602-1613, 1989

Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group. Lung Cancer 25(2): 105-113, 1999

Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group. Oncology 78(3-4): 229-236, 2010

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Annals of Oncology 6(4): 347-353, 1995

The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group. Seminars in Oncology 12(1 Suppl 2): 2-6, 1985

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Annals of Oncology 24(5): 1326-1331, 2013

A randomised phase II trial of preoperative chemotherapy of cisplatindocetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204). Yearbook of Oncology 2009: 194-195, 2009

Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. American Journal of Clinical Oncology 15(2): 163-167, 1992